

European Haemophilia Consortium Round Table of Stakeholders

Factor concentrate-related inhibitor risk in  
haemophilia A

Monday, 2<sup>nd</sup> March 2015, 13:30 to 17:30

Royal Windsor Hotel, Brussels, Belgium

**AGENDA**

13.30 – 14.30	Registration followed by lunch outside of the meeting room
14.30 – 14.40	Welcome and introduction Prof Michael Makris, EHC Medical Advisory Group
14.40 – 15.00	Plasma derived vs recombinant products and inhibitors in PUPs Prof Pier-Mannuccio Mannucci, University of Milan
15.00 – 15.20	2 <sup>nd</sup> vs 3 <sup>rd</sup> generation FVIII and inhibitors in PUPS Prof Jenny Goudemand, University of Lille
15.20 – 15.40	EUHASS and inhibitors in PUPS Dr Kathelijn Fischer, University of Utrecht
15.40 – 16.00	Coffee Break
16.00 – 16.30	Critical appraisal of inhibitor in PUP data Dr Alfonso Iorio, McMaster University
16.30 – 16.50	An epidemiologists view of the risk of inhibitors by product and how should this be assessed in future Prof Frits Rosendaal, Leiden University
16.50 – 17.00	Role of patients and patient organisations in declaring and following-up adverse event Thomas Sannié, Association Française des Hémophiles (AFH)
17.00 – 17.30	Discussions and Conclusions

